Capricor Therapeutics, which received early funding from CureDuchenne, has indicated that the FDA has decided that an Advisory Committee meeting is not warranted at this time. Capricor’s Biologics License Application (BLA) remains under Priority Review with PDUFA target action date of August 31, 2025
Read the full press release HERE
The post Regulatory Update on Capricor’s Deramiocel for Duchenne appeared first on CureDuchenne.